DexCom, Inc. (NASDAQ:DXCM) Shares Purchased by Westfield Capital Management Co. LP

Westfield Capital Management Co. LP raised its position in DexCom, Inc. (NASDAQ:DXCM) by 44.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,842,057 shares of the medical device company’s stock after acquiring an additional 876,739 shares during the quarter. DexCom accounts for about 0.9% of Westfield Capital Management Co. LP’s investment portfolio, making the stock its 21st largest holding. Westfield Capital Management Co. LP’s holdings in DexCom were worth $190,532,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of DXCM. Jennison Associates LLC boosted its stake in shares of DexCom by 1,683.2% during the 3rd quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company’s stock valued at $464,782,000 after buying an additional 6,544,102 shares during the last quarter. Canada Pension Plan Investment Board lifted its holdings in shares of DexCom by 189.1% in the second quarter. Canada Pension Plan Investment Board now owns 665,646 shares of the medical device company’s stock valued at $75,471,000 after buying an additional 435,401 shares during the period. Intech Investment Management LLC lifted its holdings in shares of DexCom by 2,083.0% in the third quarter. Intech Investment Management LLC now owns 387,330 shares of the medical device company’s stock valued at $25,967,000 after buying an additional 369,587 shares during the period. Massachusetts Financial Services Co. MA lifted its holdings in shares of DexCom by 16.9% during the second quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company’s stock valued at $276,538,000 after purchasing an additional 353,019 shares during the last quarter. Finally, Assenagon Asset Management S.A. lifted its holdings in shares of DexCom by 53.5% during the third quarter. Assenagon Asset Management S.A. now owns 989,740 shares of the medical device company’s stock valued at $66,352,000 after purchasing an additional 345,114 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $72.83 on Friday. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The stock has a market cap of $28.45 billion, a price-to-earnings ratio of 43.61, a PEG ratio of 2.28 and a beta of 1.17. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. The firm’s 50-day simple moving average is $70.61 and its 200 day simple moving average is $89.55.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Leerink Partners dropped their target price on DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Oppenheimer cut their target price on DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Royal Bank of Canada dropped their price target on DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a report on Friday, October 25th. JPMorgan Chase & Co. raised their price target on DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a report on Friday, October 25th. Finally, Barclays lowered their target price on DexCom from $138.00 to $113.00 and set an “equal weight” rating for the company in a research note on Monday, July 29th. Seven analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $104.59.

Insider Activity at DexCom

In other DexCom news, EVP Sadie Stern sold 4,259 shares of the stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total value of $318,275.07. Following the completion of the sale, the executive vice president now owns 71,192 shares in the company, valued at approximately $5,320,178.16. This trade represents a 5.64 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Jacob Steven Leach sold 746 shares of the stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. This trade represents a 0.28 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 5,431 shares of company stock valued at $399,319. 0.30% of the stock is owned by corporate insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.